South Korea · Delayed Price · Currency is KRW Kukje Pharma Statistics
Total Valuation
Kukje Pharma has a market cap or net worth of KRW 88.37 billion. The enterprise value is 100.74 billion.
| Market Cap | 88.37B |
| Enterprise Value | 100.74B |
Important Dates
The last earnings date was Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kukje Pharma has 20.36 million shares outstanding. The number of shares has increased by 0.16% in one year.
| Current Share Class | 20.36M |
| Shares Outstanding | 20.36M |
| Shares Change (YoY) | +0.16% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 12.70% |
| Owned by Institutions (%) | 6.23% |
| Float | 12.71M |
Valuation Ratios
The trailing PE ratio is 12.38.
| PE Ratio | 12.38 |
| Forward PE | n/a |
| PS Ratio | 0.51 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | 9.38 |
| P/OCF Ratio | 8.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.49, with an EV/FCF ratio of 10.69.
| EV / Earnings | 14.12 |
| EV / Sales | 0.58 |
| EV / EBITDA | 8.49 |
| EV / EBIT | 11.62 |
| EV / FCF | 10.69 |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.19 |
| Quick Ratio | 0.73 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 2.57 |
| Debt / FCF | 3.23 |
| Interest Coverage | 9.02 |
Financial Efficiency
Return on equity (ROE) is 7.71% and return on invested capital (ROIC) is 4.42%.
| Return on Equity (ROE) | 7.71% |
| Return on Assets (ROA) | 3.16% |
| Return on Invested Capital (ROIC) | 4.42% |
| Return on Capital Employed (ROCE) | 7.28% |
| Revenue Per Employee | 700.79M |
| Profits Per Employee | 28.78M |
| Employee Count | 248 |
| Asset Turnover | 1.01 |
| Inventory Turnover | 3.42 |
Taxes
In the past 12 months, Kukje Pharma has paid 1.80 billion in taxes.
| Income Tax | 1.80B |
| Effective Tax Rate | 20.15% |
Stock Price Statistics
The stock price has decreased by -26.17% in the last 52 weeks. The beta is 0.49, so Kukje Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | -26.17% |
| 50-Day Moving Average | 4,376.70 |
| 200-Day Moving Average | 4,674.43 |
| Relative Strength Index (RSI) | 50.40 |
| Average Volume (20 Days) | 197,232 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kukje Pharma had revenue of KRW 173.80 billion and earned 7.14 billion in profits. Earnings per share was 350.58.
| Revenue | 173.80B |
| Gross Profit | 93.82B |
| Operating Income | 8.67B |
| Pretax Income | 8.94B |
| Net Income | 7.14B |
| EBITDA | 11.87B |
| EBIT | 8.67B |
| Earnings Per Share (EPS) | 350.58 |
Balance Sheet
The company has 18.10 billion in cash and 30.45 billion in debt, giving a net cash position of -12.35 billion or -606.38 per share.
| Cash & Cash Equivalents | 18.10B |
| Total Debt | 30.45B |
| Net Cash | -12.35B |
| Net Cash Per Share | -606.38 |
| Equity (Book Value) | 95.32B |
| Book Value Per Share | 4,680.57 |
| Working Capital | 11.36B |
Cash Flow
In the last 12 months, operating cash flow was 10.95 billion and capital expenditures -1.52 billion, giving a free cash flow of 9.42 billion.
| Operating Cash Flow | 10.95B |
| Capital Expenditures | -1.52B |
| Free Cash Flow | 9.42B |
| FCF Per Share | 462.81 |
Margins
Gross margin is 53.98%, with operating and profit margins of 4.99% and 4.11%.
| Gross Margin | 53.98% |
| Operating Margin | 4.99% |
| Pretax Margin | 5.14% |
| Profit Margin | 4.11% |
| EBITDA Margin | 6.83% |
| EBIT Margin | 4.99% |
| FCF Margin | 5.42% |
Dividends & Yields
This stock pays an annual dividend of 30.00, which amounts to a dividend yield of 0.71%.
| Dividend Per Share | 30.00 |
| Dividend Yield | 0.71% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 4 |
| Payout Ratio | 8.56% |
| Buyback Yield | -0.16% |
| Shareholder Yield | 0.55% |
| Earnings Yield | 8.08% |
| FCF Yield | 10.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 17, 2023. It was a forward split with a ratio of 1.05.
| Last Split Date | Mar 17, 2023 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Kukje Pharma has an Altman Z-Score of 2 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2 |
| Piotroski F-Score | 6 |